← All trials
NCT06898515
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2025
- Primary completion
- Aug 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Mar 27, 2025
- Last posted
- Nov 26, 2025
- Enrollment
- 400
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Reprieve Cardiovascular, IncLead sponsor
- Baylor Scott and WhiteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.